Skip to content
Disclosery

AJU IB Investment Co., Ltd.

Follow

13F filer, CIK 1710065, Seoul, Korea Republic of

AJU IB Investment Co., Ltd. reported $91,889,533 across 8 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-07-10.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001140361-25-025427

Period
2025-06-30
Reported value
$91.9M
Holdings
8
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RAPT THERAPEUTICS INCreduced-87,066-$697K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001140361-25-025427, largest first. % of portfolio is the value over $91,889,533, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 1,047,557 shares; 2025Q1: 1,047,557 shares; 2025Q2: 1,047,557 shares 1,047,557$69M75.07%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 457,059 shares; 2025Q1: 457,059 shares; 2025Q2: 457,059 shares 457,059$19.9M21.71%0Timeline
SEERSEER INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 816,375 shares; 2025Q1: 816,375 shares; 2025Q2: 816,375 shares 816,375$1.75M1.9%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 667,742 shares; 2025Q1: 667,742 shares; 2025Q2: 667,742 shares 667,742$454K0.49%0Timeline
CARMCARISMA THERAPEUTICS INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 718,332 shares; 2025Q1: 718,332 shares; 2025Q2: 718,332 shares 718,332$281K0.31%0Timeline
RALLYBIO CORPRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 754,678 shares; 2025Q1: 754,678 shares; 2025Q2: 754,678 shares 754,678$255K0.28%0
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 175,000 shares; 2025Q1: 175,000 shares; 2025Q2: 175,000 shares 175,000$125K0.14%0
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: restricted; 2024Q4: 99,503 shares; 2025Q1: 99,503 shares; 2025Q2: 12,437 shares 12,437$99.5K0.11%-87,066

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001140361-25-025427 base2025-07-10acceptance time not in the bulk data set